Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 3 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 37 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
SWILEM PHARMACEUTICALS from Evere, company number BE0640994707, closed financial year 2025 with a result of € -7,783 after tax. For that financial year SWILEM PHARMACEUTICALS recorded a gross margin of € 30,164 and equity of € -20,398. Compared with financial year 2024, the result moved from € -8,135 to € -7,783. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 9, 2026.
€ -20,398
▼ € 7,783 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -7,783
▲ 4 % less loss than in 2024
Profit after tax over the fiscal year.
€ 19,294
▲ 75% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -26,598.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 19,912
▲ € 18,586 vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 258,436
▼ 1% vs 2024
€ 23,123 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.
€ 15,018
▲ 156% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 1,965
▼ 60% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 37,584 | € 37,783 | € 31,846 | € 30,164 | ▼ 5% |
| Profit after taxes | € 1,719 | € -22,372 | € -8,135 | € -7,783 | ▲ € 352 |
| Equity | € 17,891 | € -4,481 | € -12,615 | € -20,398 | ▼ € 7,783 |
| Total debts | € 207,853 | € 314,784 | € 292,431 | € 313,378 | ▲ 7% |
| Cash | € 36,954 | € 12,698 | € 11,045 | € 19,294 | ▲ 75% |
| Land & buildings | - | € 122,940 | € 119,342 | € 121,678 | ▲ 2% |
| Retained profit | € 11,691 | € -10,681 | € -18,815 | € -26,598 | ▼ € 7,783 |
| Bank debt | € 174,792 | € 287,533 | € 262,174 | € 258,436 | ▼ 1% |
| Balance sheet total | € 225,744 | € 310,303 | € 279,816 | € 292,979 | ▲ 5% |
Key figures of SWILEM PHARMACEUTICALS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to SWILEM PHARMACEUTICALS?
What happened at SWILEM PHARMACEUTICALS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 7,783. Source: NBB ↗
- New establishment in Evere. KBO
- BILAL SOUILEM became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 1,719 profit in 2022 to € 7,783 loss in 2025.
Paid € 2,469 in corporate taxes since 2022.
Best year ever: 2022, with € 1,719 profit.
A new publication or filing at SWILEM PHARMACEUTICALS? We notify you, reason included.
Follow SWILEM PHARMACEUTICALSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind SWILEM PHARMACEUTICALS is BILAL SOUILEM.
Directors
According to the 2025 annual accounts
BILAL SOUILEM
Director
since 2015
Establishments
Establishment units
Physical locations of this company
Provencewandelwegen 54
1140 Evere
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0640.994.707
- VAT number
- BE 0640.994.707
- Registered office
- Provencewandelwegen 54, 1140 Evere
- Names & denominations
- SWILEM PHARMACEUTICALS
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 15 October 2015
- Peppol
- Active · Active since 13 Feb 2026
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Detailhandel in farmaceutische producten